Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Pemetrexed with Radiation for Recurrent Head and Neck Cancer
NCT00573989Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2008
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Wake Forest University Health Sciences. Started Mar 2008; status: terminated.
02
Drugs
erlotinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00573989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00573989.